HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neoplasms (Cancer)

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Also Known As:
Cancer; Tumor; Tumors; Cancers; Neoplasm; Benign Neoplasm; Benign Neoplasms; Malignancy; Malignant Neoplasms; Neoplasia; Neoplasms, Benign; Malignancies; Neoplasias; Neoplasm, Benign; Neoplasm, Malignant; Neoplasms, Malignant; Malignant Neoplasm
Networked: 1324753 relevant articles (78474 outcomes, 178593 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Neoplasm Metastasis (Metastasis)
3. Breast Neoplasms (Breast Cancer)
4. Melanoma (Melanoma, Malignant)
5. Carcinoma (Carcinomatosis)

Experts

1. Zhang, Wei: 1962 articles (01/2023 - 01/2002)
2. Wang, Wei: 1781 articles (12/2022 - 09/2000)
3. Wang, Jing: 1503 articles (12/2022 - 07/2002)
4. Li, Wei: 1480 articles (11/2022 - 01/2002)
5. Li, Yan: 1431 articles (12/2022 - 03/2002)
6. Liu, Yang: 1341 articles (01/2023 - 02/2002)
7. Zhang, Li: 1269 articles (12/2022 - 03/2002)
8. Li, Jing: 1231 articles (12/2022 - 07/2001)
9. Li, Li: 1195 articles (12/2022 - 01/2002)
10. Wang, Lei: 1193 articles (12/2022 - 04/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neoplasms:
1. Immune Checkpoint InhibitorsIBA
2. Proteins (Proteins, Gene)FDA Link
3. Biomarkers (Surrogate Marker)IBA
4. Cisplatin (Platino)FDA LinkGeneric
5. VaccinesIBA
6. AntigensIBA
7. 1-phenyl-3,3-dimethyltriazene (PDT)IBA
8. Doxorubicin (Adriamycin)FDA LinkGeneric
9. Peptides (Polypeptides)IBA
10. DNA (Deoxyribonucleic Acid)IBA
03/10/2022 - "SETD7 consistently prevented epithelial to mesenchymal transition in different cancer types, and inhibition of its function appears to be associated with improved response to DNA-damaging agents in most of the analysed studies. "
01/01/2017 - "The aim of this study is to determine the efficacy of combined DNA methylation analysis of a global DNA methylation marker - LINE-1 and a tumor suppressor gene highly associated with the malignancy of HCC- RASSF1A in serum as a novel prognostic marker for diagnosis of early recurrence after curative resection.LINE-1 was hypomethylated in 66.7% (70/105) and RASSF1A promoter was hypermethylated in 73.3% (77/105) of HCC serum DNA samples by methylation specific PCR, but in none of the healthy controls: LINE-1 hypometylation (0/50) and RASSF1A hypermethylation (0/50). "
09/01/2010 - "Consistent with the biological phenotype, epigenomic studies revealed that TRAMP; Dnmt1 hypomorphic mice show dramatically reduced CpG island and promoter DNA hypermethylation in late-stage primary tumors compared to control mice. "
11/01/2017 - "Somatic sequencing of mismatch repair genes from tumor DNA, whereas not currently available in most clinical laboratories, is helpful in resolution of cases in which germline sequencing fails to identify a mutation in a mismatch repair gene. "
11/01/2016 - "A systematic investigation of DSS has revealed that the tumor accumulation ability, internalization, and endosome escape of the DSS nanocarriers, DNA unpacking and nuclear transportation are all remarkably improved by the multi-responsive "turn-on" design resulting in highly efficient gene transfection in vitro and in vivo."

Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Immunotherapy
01/01/2023 - "Due to the challenge of accurately acquiring samples and quantifying low-biomass tissue microorganisms, most studies have focused on the effect of gut microorganisms on cancer treatments, especially the efficacy of immunotherapy. "
01/01/2022 - "Recent studies suggest that highly activated, polyfunctional CD4+ T cells are incredibly effective in strengthening and sustaining overall host antitumor immunity, promoting tumor-specific CD4+ T-cell responses and effectively enhancing antitumor immunity by immunotherapy. "
01/01/2022 - "Overall, our study demonstrates that TRAIL-modified, DOX-embedded PMO nanoparticles represent a good candidate for tumor-targeted immunotherapy, which has relatively superior therapeutic efficacy and highly promising future application prospects. "
01/01/2022 - "In summary, although further research and clinical studies are still needed to solve the safety concerns and improve the efficacy of nanoplatform-based cancer immunotherapy, the recent studies presented in this review prove that nanoparticle-incorporated cancer immunotherapy is a highly promising treatment for cancer patients."
01/01/2020 - "The prognostic role of a mutant form of the tumor suppressor gene TP53 (TP53-MT) in predicting the efficacy of ICIs is highly controversial; therefore, in this study, we obtained data for 210 patients from an immunotherapy cohort, 412 patients from The Cancer Genome Atlas (TCGA)-BLCA cohort and 18 BLCA cell lines from Genomics of Drug Sensitivity in Cancer (GDSC), and we performed integrated bioinformatic analysis to explore the relationships between TP53-MT and clinical benefits derived from ICI treatment and the underlying mechanisms. "
4. Radiotherapy
5. Photochemotherapy (Photodynamic Therapy)